Chimeric Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHMMF research report →
About the company
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies.
- CEO
- Rebecca McQualter
- IPO
- 2022
- Employees
- 5
- HQ
- Carlton, VIC, AU
Price Chart
- Market Cap
- $4.10M
- P/E
- -0.10
- P/S
- 0.67
- P/B
- -0.62
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
- Gross Margin
- 74.47%
- Op Margin
- -458.31%
- Net Margin
- -420.80%
- ROE
- 2844.96%
- ROIC
- 993.55%
- Revenue
- $3.97M · 0.00%
- Net Income
- $-10,430,424 · 16.76%
- EPS
- $-0.77 · 57.22%
- Op Income
- $-15,111,460
- FCF YoY
- 3.48%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- 0.73
- Avg Volume
- 6.36K
Get TickerSpark's AI analysis on CHMMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CHMMF coverage
Recent articles, reports, and earnings notes.
No research on CHMMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHMMF report →Similar companies
Peers in the same neighborhood.